Hong Kong · Sponsored
Rethinking Biomarkers: Quantitative Continuous Scoring as an Emerging Tool for Oncologic Decision-Making
This content is sponsored. It is intended for healthcare professionals only.
The use of IHC staining of tissue samples to guide targeted treatment is widely used in clinical practice, and is recommended by expert groups for many tumor types and biomarkers. The classical approach to IHC scoring for biomarkers, such as human epidermal growth factor receptor-2 (HER2), classifies specimens as either ‘positive’ or ‘negative’, scoring samples as IHC0, 1+, 2+ or 3+ per pathologists’ visual interpretation.
